News and Trends 15 Sep 2017 Swiss-US Partners Reveal New Candidate for Autoimmune Disease Numab and Intarcia have a first candidate to combine a tri-specific antibody fragment with a mini-osmotic pump delivery system to fight autoimmune disease. Numab and Intarcia partnered in 2015 to develop a new form of treatment for diabetes, obesity and autoimmune diseases. After initial research, the team has now selected its first candidate for clinical […] September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2017 Series D Boost will Bring Artificial Intelligence to Diagnostics Worldwide Sophia Genetics has raised $30M (€25M) in Series D that will be directed to growing and improving its artificial intelligence platform for genetic diagnostics. The Swiss company Sophia Genetics has announced today a new round of funding, led by Balderton Capital, and joined by 360º Capital Partners and existing investors Invoke Capital and Alychlo. The […] September 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 11 Sep 2017 Could a Protein in Yeast hold the Secret to Escaping Age-Related Diseases? Researchers in Basel, Switzerland have identified a protein in yeast that slows protein synthesis, prolonging their lifespan. Gcn4 is a transcription factor that regulates the expression around 10% of the yeast genome. Nutrient restriction and moderate stress extend lifespan and under these conditions, yeast expresses Gcn4 to regulate protein synthesis. The aim is now to find […] September 11, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2017 Europe Gives the Antibiotic Resistance Fight a Major Cash Injection Six European countries, the UK’s Wellcome Trust and South Africa have committed €56.5M to the GARDP to work on breaking antibiotic resistance. The Global Antibiotic Research and Development Partnership (GARDP) has received this week €56.5M of funding to boost its activity, focused in promoting the development of new antibiotics. The investment comes mainly from Germany, […] September 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2017 Swiss Biotech Raises €8M in First Closing of Series B to Develop Cancer Vaccines AMAL Therapeutics has raised €8M to push its colorectal cancer vaccine ATP128 into clinical trials and keep developing its tumor vaccine pipeline. AMAL Therapeutics, a young biotech based in Geneva, is getting a boost for its pipeline of cancer vaccines thanks to a new funding round. The first tranche of its Series B fundraising has gathered €8M (CHF 8.8M) […] September 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 21 Aug 2017 First-in-Human Trial will test a New Cancer Therapy from Switzerland Cellestia Biotech will start human trials with CB-103, an anticancer drug targeting the Notch signaling pathway, known for its ubiquity in cancer. Cellestia Biotech, based in Basel, has announced it received full approval to start clinical trials in Spain with CB-103, a new class of drug that targets an ubiquitous cancer mechanism. The drug is a […] August 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2017 Swiss Researchers Unveil Cancer Immunotherapy Resistance Mechanism Scientists from the University of Zurich have identified an epigenetic control switch responsible for turning melanoma unresponsive to immune checkpoint inhibitors. A study published this week in Cell Reports describes a mechanism that might be responsible for the development of resistance to cancer immunotherapy. The culprit turned out to be Ezh2, a protein that controls genetic […] July 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 25 Jul 2017 Trouble in Paradise: How Biotech is Fighting Tropical Diseases Tropical diseases are often neglected until an outbreak causes worldwide panic. Here’s how European biotech is preparing for the next one. “What we really need is a very fast and cheap way to develop vaccines,” biotech godfather Greg Winter told me earlier this year. Such precautionary measures may well be on our minds as Europe […] July 25, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2017 Shire In-Licenses Swiss Antibody for Hemophilia A to Compete with Roche Shire has bought exclusive worldwide rights to develop and commercialize a bispecific antibody from Novimmune that could improve the treatment of hemophilia A. Novimmune is a biotech from Geneva that specializes in developing antibodies. Back in 2015, it struck a research collaboration with Baxalta, which has since been acquired Shire. The Irish pharma has now decided to […] July 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2017 Swiss Biotech Starts Phase II Trial to Treat Motor Symptoms of Parkinson’s Prexton Therapeutics has launched a Phase II trial to test whether its drug foliglurax can treat the motor complications of standard levodopa therapy. The Phase II trial will enroll 165 patients across the UK, Germany, France, Austria, Spain and Italy to monitor the effects of Prexton’s foliglurax. The company is looking for patients that have been treated […] July 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2017 Swiss Scientists Have Designed New Proteins to Treat Muscular Dystrophy Researchers at the University of Basel have designed two proteins that can reverse congenital muscular dystrophy and increase the lifespan of mice. Congenital muscular dystrophy (CMD) englobes several genetic diseases that cause muscle weakness from birth. As patients age, the disease becomes more severe and affects breathing, often leading to death before adulthood. Unfortunately, there […] June 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 26 Jun 2017 Meet the Gynecologist at the Helm of Geneva’s Star Biotech Ernest Loumaye began as a doctor at a university hospital and is now CEO of ObsEva. We chatted about how biotech supports women’s health. ObsEva, one of the top biotechs in Geneva that made this year’s first IPO for a huge €90M, is not Ernest Loumaye’s first company. Though he began as the gynecologist in charge of the reproductive […] June 26, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email